The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.
Blood Adv
; 7(23): 7279-7289, 2023 12 12.
Article
in En
| MEDLINE
| ID: mdl-37738125
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Antineoplastic Agents
Limits:
Child
/
Humans
Language:
En
Journal:
Blood Adv
Year:
2023
Document type:
Article
Country of publication:
Estados Unidos